



PATENT APPLICATION DOCKET NO.: 3589.1008-002

	II	LINE	MONITED STATES PAT	ENT AND TRADEM.	ARK OFFICE
Applica	ants:		Carlo Croce and George C	alin	
Applica	ation No	.:	10/706,798	Group:	1633
Filed:			November 12, 2003	Examiner:	Quang Nguyen, Ph.D.
Confir	mation N	lo.:	8331		·
For:			COMPOSITIONS AND NAND THERAPY	METHODS FOR CANO	CER DIAGNOSIS
			I hereby certify that this correspor States Postal Service with sufficient envelope addressed to Commissione VA 22313-1450, or is being facsimi and Trademark Office on: Twee	postage as First Class Mail in an r for Patents, P.O. Box 1450, Alex	United andria,
	<u>s</u>	UPPL:	EMENTAL INFORMAT	ION DISCLOSURE	<u>STATEMENT</u>
Commi P.O. Bo	top Ame issioner : ox 1450 dria, VA	for Pate	ents		
Sir:					
This Su	upplemei	ntal Inf	ormation Disclosure States	nent is submitted:	
	(Within any national stag	one of the	1.97(b), or e following time periods: three months of ternational application; or before the ma Request for Continued Examination).	of filing national application (other iling date of a first office action on	than a CPA) or date of entry of the the merits in a non-provisional application,
\boxtimes		a Statei a \$180.	1.97(c) together with eithe ment under 37 CFR 1.97(e) 00 fee under 37 CFR 1.17(37 CFR 1.97(b) time period, but before	, as checked below, or (p), or	whichever occurs first)
		er 37 CFR 1.97(d) together with: a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)			
	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application file. (Filed after payment of issue fee)				

06/14/2007 RMEBRAHT 00000039 10706798

01 FC:1806

180.00 OP

Statement	Under 3	7 CFR	1.97(e)

	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
Statem	nent Under 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000			
	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.			
\boxtimes	Enclosed herewith is form PTO-1449:			
	Copies of the cited references, C1-C3, are enclosed.			
	Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.			
	Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.			
	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.			
	The "concise explanation" requirement (non-English references) for reference [] CFR 1.98(a)(3) is satisfied by:			
	the explanation provided on the attached sheet.			
	the explanation provided in the Specification.			
	submission of the enclosed International Search Report.			
	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.			
	the enclosed English language abstract.			

			ving non-published pending app IDS Reference - Do Not Scan" to the front of ed	
Examiner's Initials				
		U.S. Patent Application N	Io. [], by [inventor(s)], filed], Docket No.: []
		U.S. Patent Application N	o. [], by [inventor(s)], filed [], Docket No.: []
		U.S. Patent Application N	lo. [], by [inventor(s)], filed [], Docket No.: []
		Examiner	Date	
		except any application file	ed application, including the cur ed on or after June 30, 2003, wh apper (IFW) system and is availa	ich has been scanned into
			ed application, including the cur ior application, U.S. Application aimed.	
		r is requested to return a corre considered with the next	py of the above list of pending a office communication.	applications indicating which
It is re	quested	that the information disclo	sed herein be made of record in	this application.
Metho	d of pa	yment:		
\boxtimes			s enclosed, or the fee has been it of this Statement is enclosed.	ncluded in the check with
	Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.			
\boxtimes	Please 0380.	charge any deficiency in f	ees and credit any overpayment	to Deposit Account 08-
		I	Respectfully submitted,	
		I	HAMILTON, BROOK, SMITH	& REYNOLDS, P.C.
]] 	Eric M. Balicky Registration No. 57,020 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	

Concord, MA 01742-9133
Dated: June 11, 2007

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3589.1008-002		APPLICATION NO. 10/706,798	
SUPPLEMENTAL INFORMATION				
DISCLOSURE STATEMENT	FIRST NAMED INVEN	TOR	FILING DATE	3
IN AN APPLICATION	Carlo Croce		November 12, 2003	
(June 11, 2007) 2 JUN 14 2 %	<u> </u>	· · · · · ·		·
(June 11, 2007)	EXAMINER	CONFI	RMATION NO.	GROUP
(Use several sheets if necessary)	Quang Nguyen, Ph.D.	8331		1633
PADENJAHKOK	L	<u> </u>		I

	<u> </u>	U.S	S. PATENT DO	CUMENTS				
EXAM -INER INI- TIAL			PUBLICATI	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY		NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		
	A3			,				
		FORE	ZIGN PATENT	DOCUMEN	TTS			
		FURE	AGN PAIENI	DOCUMEN	113			
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY		TENTEE OR APPLICANT TED DOCUMENT	TRANS YES	SLATION NO	
	В3							
						D.		
	•	OTHER DOCUMENTS (I	ncluding Autho	r, Title, Dat	e, Pertinent Pages,	Etc.)		
	C1	Calin, G.A., et al., "A Micro Lymphocytic Leukemia," N.				ession in	Chronic	
	C2	Calin, G.A., et al., "MicroRNAs and Leukemias: How Strong is the Connection?" Leukemia Res. 30:653-655 (2006).						
	C3	Kroese, M., et al., "Genetic" Genet. Med. 6:475-480 (2004)		aluation: Car	We Answer the Key	Questio	ns?"	

EXAMINER	·	DATE CONSIDERED